ALK-Abelló A/S (LON: 0OIR)

Market Cap	3.87B
Revenue (ttm)	600.68M
Net Income (ttm)	87.60M
Shares Out	n/a
EPS (ttm)	0.39
PE Ratio	44.16
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,474
Average Volume	56,597
Open	148.70
Previous Close	148.70
Day's Range	148.20 - 151.90
52-Week Range	11.05 - 20.60
Beta	0.61
RSI	45.98
Earnings Date	Feb 19, 2025

About ALK-Abelló

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solut...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1923
• Employees: 2,824
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0OIR

Financial Performance

In 2023, ALK-Abelló's revenue was 4.82 billion, an increase of 6.94% compared to the previous year's 4.51 billion. Earnings were 486.00 million, an increase of 45.07%.

Financial numbers in DKK